Archives of Medical Science最新文献_第5页

A double-blind randomized controlled trial comparing the effects of the Mézières method and Isostretching postures in sagittal stand position evaluated through the Spinal Mouse^® in elite rhythmic gymnasts with low back pain. 一项双盲随机对照试验，通过Spinal Mouse®评估msamzi<e:1>方法和矢状位等拉伸姿势对优秀艺术体操运动员腰痛的影响。

IF 3 4区医学

Archives of Medical Science Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/202432

Jasemin Todri, Erda Qorri, Juan Martinez-Fuentes, Orges Lena

引用次数: 0

Establishing reference intervals for serum glutathione reductase in healthy adults. 建立健康成人血清谷胱甘肽还原酶参考区间。

IF 3.3 4区医学

Archives of Medical Science Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/199536

Qian Liu, Hongxia Wang, Shanshan Shen, Fang Yang, Zongze Han, Enyue Liu, Fumeng Yang

{"title":"Establishing reference intervals for serum glutathione reductase in healthy adults.","authors":"Qian Liu, Hongxia Wang, Shanshan Shen, Fang Yang, Zongze Han, Enyue Liu, Fumeng Yang","doi":"10.5114/aoms/199536","DOIUrl":"10.5114/aoms/199536","url":null,"abstract":"Introduction: Glutathione reductase (GR) is a key enzyme that catalyzes the reduction of oxidized glutathione to its reduced form, playing a vital role in protecting cells from oxidative damage caused by the accumulation of reactive oxygen species. This study employed the ultraviolet enzymatic method to measure serum GR activity, aiming to investigate its distribution among apparently healthy adults and preliminarily establish reference intervals for serum GR.Material and methods: A total of 6,180 apparently healthy individuals participated in this study. Serum GR activity was measured using the AU5800 fully automated biochemical analyzer and its corresponding commercial kit. The Kolmogorov-Smirnov test was used to analyze the distribution of serum GR activity. Following the guidelines of C28-A3 and WS/T 402-2024, the reference interval for serum GR was determined using the bilateral percentile method, covering the range from the 2.5th to the 97.5th percentile.Results: Serum GR activity in this study exhibited a non-normal distribution. Significant gender-based differences in GR activity were observed, while no significant variations were found across different age groups. Based on these findings, gender-specific reference intervals for serum GR were established: 26.6-51.8 U/l for males and 29.7-55.3 U/l for females.Conclusions: This study is the first to establish gender-specific reference intervals for serum GR in apparently healthy adults. These intervals provide essential guidance for health screening and improve the diagnosis and management of related clinical conditions.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"21 4","pages":"1397-1404"},"PeriodicalIF":3.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12509819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel heterozygous mutation in the gelsolin gene causes Finnish gelsolin amyloidosis associated with nephropathy and thrombotic microangiopathy. gelsolin基因的一种新的杂合突变导致芬兰gelsolin淀粉样变性与肾病和血栓性微血管病相关。

IF 3 4区医学

Archives of Medical Science Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/202433

Hong Liang, Huixin Zheng, Jing Lin, Ke Lin

引用次数: 0

Clinical effects of stent implantation on lower extremity deep venous thrombosis with severe iliac vein stenosis. 支架置入术治疗重度髂静脉狭窄伴下肢深静脉血栓的临床疗效。

IF 3.3 4区医学

Archives of Medical Science Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/199513

Shuaishuai Mao, Wei Huang, Aoyun Ren, Jiaqing Luo

{"title":"Clinical effects of stent implantation on lower extremity deep venous thrombosis with severe iliac vein stenosis.","authors":"Shuaishuai Mao, Wei Huang, Aoyun Ren, Jiaqing Luo","doi":"10.5114/aoms/199513","DOIUrl":"10.5114/aoms/199513","url":null,"abstract":"Introduction: Lower extremity deep venous thrombosis (DVT) with severe iliac vein stenosis is common and can lead to significant morbidity and mortality. Treatment options are limited, and the safety and effectiveness of stent implantation are unclear. This study evaluated stent implantation for treating this condition.Material and methods: This observational clinical study analyzed data from DVT patients who underwent stent implantation at Changxing People's Hospital, Zhejiang, China, between 2017 and 2022. Patients who received stent implantation comprised the experimental group, while those who did not formed the control group. All patients underwent thrombus aspiration and/or stent implantation, and outcomes were compared between the two groups during follow-up.Results: In this study, in 60 cases the procedures were completed with no significant changes in hemoglobin, hematoma formation, thrombolytic time, or bleeding complications (p > 0.05). The stent group demonstrated a higher thrombolytic rate and lower limb swelling (p < 0.05). During a mean follow-up of 15.2 ±5.8 months, 1 stent patient developed DVT and another had stenosis, while the control group had 3 DVT recurrences and 5 iliac vein occlusions. The stent group had a higher deep vein patency rate and lower iliac vein occlusion rate (p = 0.01), with similar DVT recurrence rates (p = 0.34). Additionally, the stent group had higher Chronic Venous Insufficiency Questionnaire (CIVIQ) (t = 2.54, p = 0.01) and lower CEAP scores (t = 3.72, p < 0.01).Conclusions: Our study suggests that stent implantation is an effective and safe treatment option for DVT with severe iliac vein stenosis.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"21 4","pages":"1235-1240"},"PeriodicalIF":3.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12509824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The protective effect of sodium-glucose cotransporter 2 inhibitors and the incidence of ovarian cancer: a nationwide cohort preliminary study. 钠-葡萄糖共转运蛋白2抑制剂对卵巢癌发病率的保护作用：一项全国性队列初步研究

IF 3.3 4区医学

Archives of Medical Science Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/196382

Ke-Hsin Ting, Jing-Yang Huang, Pei-Lun Liao, Chia-Yi Lee, Shun-Fa Yang

{"title":"The protective effect of sodium-glucose cotransporter 2 inhibitors and the incidence of ovarian cancer: a nationwide cohort preliminary study.","authors":"Ke-Hsin Ting, Jing-Yang Huang, Pei-Lun Liao, Chia-Yi Lee, Shun-Fa Yang","doi":"10.5114/aoms/196382","DOIUrl":"10.5114/aoms/196382","url":null,"abstract":"Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are commonly used antihyperglycemic medications that also exhibit anti-inflammatory and antioxidant effects. Ovarian cancer, a common gynecological neoplasm, is associated with increased inflammation and oxidative stress. Thus, this study investigated the correlation between the usage of SGLT2 inhibitors and the incidence of ovarian cancer in a population with type 2 diabetes mellitus (T2DM).Material and methods: A retrospective cohort study was conducted, and patients with T2DM were divided into those who used SGLT2 inhibitors and those who did not. A total of 163 668 and 327 336 patients with T2DM were categorized into the SGLT2 inhibitor and control groups, respectively. The primary outcome was the development of ovarian cancer, as identified using diagnostic codes and laboratory examination findings. Cox proportional hazard regression was adopted to yield the adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for ovarian cancer events between the two groups.Results: A total of 167 and 222 patients developed ovarian cancer in the SGLT2 inhibitor and control groups, respectively. The incidence of ovarian cancer was significantly lower in the SGLT2 inhibitor group than in the control group (adjusted hazard ratio: 0.73, 95% CI: 0.60-0.89, p = 0.0023). Subgroup analysis stratified by oral medications revealed that the effect of SGLT2 inhibitors on ovarian cancer development was significantly different from the effects of biguanides, sulfonylureas, α-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors (p < 0.05).Conclusions: This preliminary study showed that the administration of SGLT2 inhibitors in patients with T2DM is associated with a lower incidence of ovarian cancer.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"21 4","pages":"1279-1288"},"PeriodicalIF":3.3,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12509869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of GSDMs in the immune microenvironment of prostate cancer and their impact on patient prognosis: a comprehensive analysis based on the TCGA-PRAD database. GSDMs在前列腺癌免疫微环境中的作用及其对患者预后的影响：基于TCGA-PRAD数据库的综合分析

IF 3 4区医学

Archives of Medical Science Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/202123

Kai Liu, Chundong D Ji, Xuhua Qiao

引用次数: 0

Neurological manifestations in an adult with phenylketonuria. 苯丙酮尿症成人的神经学表现。

IF 3 4区医学

Archives of Medical Science Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/201449

Patryk Sochań, Michał Białobrzewski, Patrycja J Sochań, Izabela Domitrz

引用次数: 0

Effectiveness of endoscopic transnasal pituitary surgery versus antibiotic therapy in the management of pituitary abscess: a report of two cases. 内镜下经鼻垂体手术与抗生素治疗在垂体脓肿治疗中的效果：两例报告。

IF 3 4区医学

Archives of Medical Science Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/201450

Chunan Cao, Jiajun Liu, Sheng Zhang, Da He, Jincheng Zhao, Yutong Yang, Bo Shu, Hui Tong, Hongchuan Gan

引用次数: 0

Trends in stroke prevalence caused by an elevated body mass index in the European population. 欧洲人群中身体质量指数升高引起的中风流行趋势

IF 3.3 4区医学

Archives of Medical Science Pub Date : 2025-02-22 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/199362

Mengjun Tao, Yang Wu, Huiru Cao, Hui Peng

{"title":"Trends in stroke prevalence caused by an elevated body mass index in the European population.","authors":"Mengjun Tao, Yang Wu, Huiru Cao, Hui Peng","doi":"10.5114/aoms/199362","DOIUrl":"10.5114/aoms/199362","url":null,"abstract":"Introduction: This study investigated the complex relationship between an elevated body mass index (BMI) and stroke risk in Europe amidst rising obesity rates and an aging population.Material and methods: A joinpoint regression model was used to fit the data on stroke mortality rates attributed to an elevated BMI. The age period cohort model was used to analyze the effects of age, period, and birth cohort on trends in stroke prevalence related to an elevated BMI from 1990-2019 in the European context. A Bayesian age-period-cohort model was used to project age-standardized stroke mortality attributed to elevated BMI in Europe from 2020 to 2044.Results: Stroke mortality rates attributed to an elevated BMI displayed a wave-like declining trend in Europe, decreasing from 21.73/100,000 in 1990 to 14.01/100,000 in 2019. The most substantial decline in stroke mortality rate occurred between 2003 and 2013 (age period cohort analysis: -4.10%, 95% CI: -4.44 to -3.75; p < 0.001). Male mortality rates decreased from 21.48/100,000 in 1990 to 15.45/100,000 in 2019, while female rates declined more significantly from 21.40/100,000 in 1990 to 12.48/100,000 in 2019. Age-standardized stroke mortality due to elevated BMI is projected to decline in Europe over the next 25 years. Age-standardized stroke mortality due to increased BMI is expected to continue declining in Europe over the next 25 years, with projected reductions of 12.99% in males and 13.01% in females by 2044.Conclusions: From 1990 to 2019, stroke mortality rates associated with elevated BMI in Europe steadily increased. However, projections suggest a slight decline in the near future. Given these trends, there is an urgent need to enhance weight management for stroke patients and increase public health awareness, particularly among men and the elderly, to reduce stroke-related mortality.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"21 3","pages":"766-774"},"PeriodicalIF":3.3,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings. 2024年：心血管疾病年——脂蛋白年(a)。研究进展和新发现。

IF 3 4区医学

Archives of Medical Science Pub Date : 2025-02-22 eCollection Date: 2025-01-01 DOI: 10.5114/aoms/202213

Bożena Sosnowska, Peter P Toth, Alexander C Razavi, Alan T Remaley, Roger S Blumenthal, Maciej Banach

{"title":"2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.","authors":"Bożena Sosnowska, Peter P Toth, Alexander C Razavi, Alan T Remaley, Roger S Blumenthal, Maciej Banach","doi":"10.5114/aoms/202213","DOIUrl":"10.5114/aoms/202213","url":null,"abstract":"Elevated plasma lipoprotein(a) [Lp(a)] levels, which occur in as many as 1.5 billion people worldwide, are an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Unlike low-density lipoprotein cholesterol, Lp(a) levels are approximately 70-90% genetically determined. Currently, no approved pharmacological therapies specifically target lowering Lp(a) concentrations. Several drugs, mainly RNA-based therapies, that specifically and potently lower Lp(a), are under investigation. Three of these new therapeutic agents are advancing through clinical development to evaluate whether reducing Lp(a) levels can decrease cardiovascular risk. The outcomes of these trials could potentially transform cardiovascular disease prevention strategies; however, once approved, the drugs will likely be used for secondary prevention, and ongoing strategies for managing elevated Lp(a) in primary prevention will be important. Lipoprotein(a) research is a rapidly evolving field, but unanswered questions remain concerning the physiological function of Lp(a) and its true pathogenic mechanisms. This review of Lp(a) research focuses on new findings and clinical trial results that appeared in 2024.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"21 2","pages":"355-373"},"PeriodicalIF":3.0,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0